Date | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) |
---|
CEO | Mr. Ilan Danieli |
IPO Date | June 30, 2017 |
Location | United States |
Headquarters | 4 Science Park |
Employees | 51 |
Sector | Healthcare |
Industries |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Past 5 years
USD 176.56
USD 23.32
USD 1.01
USD 3.88
USD 6.68
USD 5.27
USD 1.91
USD 28.75
USD 2.08
USD 52.75
StockViz Staff
February 5, 2025
Any question? Send us an email